Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg)

• Published in: BMC pulmonary medicine 2024-11, Vol.24 (1), p.572-8, Article 572
• Main Authors: Krauss, Ekaterina, Tello, Silke, Naumann, Jennifer, Wobisch, Sandra, Ruppert, Clemens, Kuhn, Stefan, Mahavadi, Poornima, Majeed, Raphael W, Bonniaud, Philippe, Molina-Molina, Maria, Wells, Athol, Hirani, Nik, Vancheri, Carlo, Walsh, Simon, Griese, Matthias, Crestani, Bruno, Guenther, Andreas
• Format: Article
• Language: English
• Subjects: Accuracy; Adult; Algorithms; Artificial intelligence; Biobanks; Biological Specimen Banks; Biomarkers; Biopsy; Care and treatment; Child; Clinical trials; Consortia; Development and progression; Diagnosis; Dosage and administration; Ethylenediaminetetraacetic acid; eurILDreg; eurIPFreg; Europe; European Registry and Biobank for Interstitial Lung Diseases; Health aspects; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive agents; Information management; Informed consent; Interstitial Lung Disease; Lavage; Lung diseases; Lung diseases, Interstitial; Lung Diseases, Interstitial - diagnosis; Lung Diseases, Interstitial - therapy; Lungs; Medical ethics; Medical innovations; Medical research; Medicine, Experimental; Patients; Pediatrics; Pneumonia; Prognosis; Pulmonary fibrosis; Quality of Life; Registries; Registries (in medicine); Research Design; Respiratory function; Sensors; Study Protocol; Transplantation; VOCs; Volatile organic compounds
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-024-03389-9

Interstitial lung diseases (ILDs), encompassing both pediatric and adult cases, present a diverse spectrum of chronic conditions with variable prognosis. Despite limited therapeutic options beyond antifibrotic drugs and immunosuppressants, accurate diagnosis is challenging, often necessitating invasive procedures that may not be feasible for certain patients. Drawn against this background, experts across pediatric and adult ILD fields have joined forces in the RARE-ILD initiative to pioneer novel non-invasive diagnostic algorithms and biomarkers. Collaborating with the RARE-ILD consortium, the eurILDreg aims to comprehensively describe different ILDs, analyze genetically defined forms across age groups, create innovative diagnostic and therapeutic biomarkers, and employ artificial intelligence for data analysis. The foundation of eurILDreg is built on a comprehensive parameter list developed and adopted by clinical experts, encompassing over 1,800 distinct parameters related to patient history, clinical examinations, diagnosis, lung function and biospecimen collection. This robust dataset is further enriched with daily assessments captured through the patientMpower app, including handheld spirometry and exercise tests, conducted on approximately 350 patients over the course of a year. This approach involves app-based daily assessments of quality of life, symptom tracking, handheld spirometry, saturation measurement, and the 1-min sit-to-stand test (1-STST). Additionally, pediatric data from the ChILD-EU registry will be integrated into the RARE-ILD Data Warehouse, with the ultimate goal of including a total of 4.000 ILD patients and over 100.000 biospecimen. The collaborative efforts within the consortium are poised to streamline research endeavors significantly, promising to advance patient-centered care, foster innovation, and shape the future landscape of interstitial lung disease research and healthcare practices. EurILDreg is registered in the German Clinical Trials Register (DRKS 00028968, 26.07.2022), and eurIPFreg is registered in ClinicalTrials.gov (NCT02951416).